• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MMJ
Click for more information
4.76% 11.0¢

MMJ GROUP HOLDINGS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MMJ Release of Shares from Voluntary Escrow-MMJ.AX 12/09/16
MMJ Preliminary Final Report-MMJ.AX PRICE SENSITIVE01/09/16
MMJ MMJ to Commence Phase 2 Clinical Trial on Pediatric Epilepsy-MMJ.AX PRICE SENSITIVE15/08/16
MMJ Appointment of Chief Operating Officer-MMJ.AX 15/08/16
MMJ Final Director's Interest Notice-MMJ.AX 11/08/16
MMJ Director Resignation-MMJ.AX 11/08/16
MMJ MMJ Enters Strategic Land Package Agreement-MMJ.AX PRICE SENSITIVE03/08/16
MMJ Quarterly Update and Appendix 4C-MMJ.AX PRICE SENSITIVE29/07/16
MMJ Investor Presentation-MMJ.AX 21/07/16
MMJ Q&A Session with MMJ's Managing Director-MMJ.AX 18/07/16
MMJ Notice Under Section 708A(5)(e) of the Corporations Act-MMJ.AX 14/07/16
MMJ Change of Director's Interest Notice x 3-MMJ.AX 08/07/16
MMJ Change of Director's Interest Notice-MMJ.AX 08/07/16
MMJ Appendix 3B-MMJ.AX 08/07/16
MMJ Canada Takes Steps Towards Recreational Legalisation-MMJ.AX PRICE SENSITIVE05/07/16
MMJ Appointment of Group CFO-MMJ.AX 04/07/16
MMJ Health Canada Grants MMJ License to Produce Medical Cannabis-MMJ.AX PRICE SENSITIVE30/06/16
MMJ Trading Halt-MMJ.AX PRICE SENSITIVE28/06/16
MMJ MMJ Appoints Pharmaceutical Professionals to Drive Strategy-MMJ.AX 14/06/16
MMJ Quarterly Update and Appendix 4C-MMJ.AX PRICE SENSITIVE02/05/16
MMJ Appendix 3B-MMJ.AX 27/04/16
MMJ Results of Meeting-MMJ.AX 22/04/16
MMJ MMJ Marks AUS Market Entry with Two Strategic Partnerships-MMJ.AX PRICE SENSITIVE20/04/16
MMJ Release from Escrow-MMJ.AX 11/04/16
MMJ Market Briefing Interview30/03/16
MMJ Progress on MMJ's Lucky Lake Facility MMPR ApplicationPRICE SENSITIVE30/03/16
MMJ Notice of General Meeting/Proxy Form15/03/16
MMJ Notice Under Section 708A(5)(e) of the Corporations Act07/03/16
MMJ Appendix 3B07/03/16
MMJ Satipharm Gelpell Outperforms Sativex in Phase 1 TrialPRICE SENSITIVE03/03/16
MMJ Appendix 3B01/03/16
MMJ Capital RaisingPRICE SENSITIVE01/03/16
MMJ Canadian Court Ruling to Support Industry01/03/16
MMJ Half Yearly Report and Accounts01/03/16
MMJ Trading HaltPRICE SENSITIVE26/02/16
MMJ Cannabis Legalisation Gives MMJ the Green LightPRICE SENSITIVE25/02/16
MMJ Investor Presentation15/02/16
MMJ Successful Results of Phase 1 Clinical TrialPRICE SENSITIVE11/02/16
MMJ Extension of Yissum Licensing AgreementPRICE SENSITIVE10/02/16
MMJ MMJ Completes Duncan MMPR Pre-License InspectionPRICE SENSITIVE05/02/16
MMJ Quarterly Update Report01/02/16
MMJ Appendix 4C - quarterlyPRICE SENSITIVE01/02/16
MMJ MMJ Receives Notice of Pre-Licence Inspection at DuncanPRICE SENSITIVE14/01/16
MMJ Trading HaltPRICE SENSITIVE13/01/16
MMJ Appendix 3B10/12/15
MMJ Results of Meeting24/11/15
MMJ Investor Presentation23/11/15
MMJ Satipharm Completes Wholesale TransactionPRICE SENSITIVE19/11/15
MMJ Duncan Facility Ready for Immediate Pre-License Inspection04/11/15
MMJ Quarterly Update Report02/11/15
MMJ Appendix 4C - quarterlyPRICE SENSITIVE02/11/15
MMJ Phase 1 Clinical Trial Commences27/10/15
MMJ Broker Research Report26/10/15
MMJ Notice of Annual General Meeting/Proxy Form23/10/15
MMJ Capital Raising & MMJ to Enter Australian MC MarketPRICE SENSITIVE23/10/15
MMJ Trading HaltPRICE SENSITIVE21/10/15
MMJ Market UpdatePRICE SENSITIVE13/10/15
MMJ Innovations TV Series to Showcase MMJ on Discovery Channel09/10/15
MMJ Broker Research Report08/10/15
MMJ Annual Report to shareholders07/10/15
MMJ Appendix 3B - Quotation of Restricted Securities17/09/15
MMJ Appendix 3B08/09/15
MMJ Release of Shares from Mandatory Escrow03/09/15
MMJ Results of Meeting03/09/15
MMJ Appendix 4G01/09/15
MMJ Appendix 4E and Full Year Statutory AccountsPRICE SENSITIVE01/09/15
MMJ First Revenues Generated Upon Launch of Satipharm.comPRICE SENSITIVE31/08/15
MMJ Trading HaltPRICE SENSITIVE27/08/15
MMJ Appendix 3B26/08/15
MMJ MMJ to Commence Phase 1 Clinical Study Late 2015PRICE SENSITIVE24/08/15
MMJ Becoming a substantial holder21/08/15
MMJ Final Director's Interest Notice x 221/08/15
MMJ Board and Leadership Changes20/08/15
MMJ APP Securities Research Report18/08/15
MMJ Managing Director's Letter to Shareholders10/08/15
MMJ Completion of Capital Raising05/08/15
MMJ Notice of General Meeting/Proxy Form04/08/15
MMJ Initial Director's Interest Notice (Replacement)03/08/15
MMJ MD Remuneration & Directors' Interests Notices03/08/15
MMJ Quarterly Activities Report31/07/15
MMJ Appendix 4C - quarterlyPRICE SENSITIVE31/07/15
MMJ PhytoTech MMJ Merger and Capital Raising CompletedPRICE SENSITIVE28/07/15
MMJ Appendix 3B28/07/15
MMJ Trading HaltPRICE SENSITIVE23/07/15
MMJ Investor Presentation - Replacement14/07/15
MMJ Investor Presentation14/07/15
MMJ PYL Significantly Expands Medical Cannabis Product PortfolioPRICE SENSITIVE13/07/15
MMJ ASX Waiver of Listing Rule 14.710/07/15
MMJ Oral Formulations Advance Towards Phase 1 Clinical TrialsPRICE SENSITIVE06/07/15
MMJ MMJ Merger Unconditional02/07/15
MMJ Results of Meeting29/06/15
MMJ PhytoTech Launches New Website23/06/15
MMJ PYL and MMJ on Track for Revenues in JulyPRICE SENSITIVE28/05/15
MMJ Notice of General Meeting/Proxy Form25/05/15
MMJ PYL-MMJ Merger UpdatePRICE SENSITIVE25/05/15
MMJ Appendix 3B08/05/15
MMJ Yissum Licensing Agreement AmendmentPRICE SENSITIVE07/05/15
MMJ Appendix 4C - quarterlyPRICE SENSITIVE28/04/15
MMJ Presentation21/04/15
MMJ PYL-MMJ Investor Presentation20/04/15
MMJ Release of Shares from Voluntary Escrow-MMJ.AX
12/09/16
MMJ Preliminary Final Report-MMJ.AX
01/09/16PRICE SENSITIVE
MMJ MMJ to Commence Phase 2 Clinical Trial on Pediatric Epilepsy-MMJ.AX
15/08/16PRICE SENSITIVE
MMJ Appointment of Chief Operating Officer-MMJ.AX
15/08/16
MMJ Final Director's Interest Notice-MMJ.AX
11/08/16
MMJ Director Resignation-MMJ.AX
11/08/16
MMJ MMJ Enters Strategic Land Package Agreement-MMJ.AX
03/08/16PRICE SENSITIVE
MMJ Quarterly Update and Appendix 4C-MMJ.AX
29/07/16PRICE SENSITIVE
MMJ Investor Presentation-MMJ.AX
21/07/16
MMJ Q&A Session with MMJ's Managing Director-MMJ.AX
18/07/16
MMJ Notice Under Section 708A(5)(e) of the Corporations Act-MMJ.AX
14/07/16
MMJ Change of Director's Interest Notice x 3-MMJ.AX
08/07/16
MMJ Change of Director's Interest Notice-MMJ.AX
08/07/16
MMJ Appendix 3B-MMJ.AX
08/07/16
MMJ Canada Takes Steps Towards Recreational Legalisation-MMJ.AX
05/07/16PRICE SENSITIVE
MMJ Appointment of Group CFO-MMJ.AX
04/07/16
MMJ Health Canada Grants MMJ License to Produce Medical Cannabis-MMJ.AX
30/06/16PRICE SENSITIVE
MMJ Trading Halt-MMJ.AX
28/06/16PRICE SENSITIVE
MMJ MMJ Appoints Pharmaceutical Professionals to Drive Strategy-MMJ.AX
14/06/16
MMJ Quarterly Update and Appendix 4C-MMJ.AX
02/05/16PRICE SENSITIVE
MMJ Appendix 3B-MMJ.AX
27/04/16
MMJ Results of Meeting-MMJ.AX
22/04/16
MMJ MMJ Marks AUS Market Entry with Two Strategic Partnerships-MMJ.AX
20/04/16PRICE SENSITIVE
MMJ Release from Escrow-MMJ.AX
11/04/16
MMJ Market Briefing Interview
30/03/16
MMJ Progress on MMJ's Lucky Lake Facility MMPR Application
30/03/16PRICE SENSITIVE
MMJ Notice of General Meeting/Proxy Form
15/03/16
MMJ Notice Under Section 708A(5)(e) of the Corporations Act
07/03/16
MMJ Appendix 3B
07/03/16
MMJ Satipharm Gelpell Outperforms Sativex in Phase 1 Trial
03/03/16PRICE SENSITIVE
MMJ Appendix 3B
01/03/16
MMJ Capital Raising
01/03/16PRICE SENSITIVE
MMJ Canadian Court Ruling to Support Industry
01/03/16
MMJ Half Yearly Report and Accounts
01/03/16
MMJ Trading Halt
26/02/16PRICE SENSITIVE
MMJ Cannabis Legalisation Gives MMJ the Green Light
25/02/16PRICE SENSITIVE
MMJ Investor Presentation
15/02/16
MMJ Successful Results of Phase 1 Clinical Trial
11/02/16PRICE SENSITIVE
MMJ Extension of Yissum Licensing Agreement
10/02/16PRICE SENSITIVE
MMJ MMJ Completes Duncan MMPR Pre-License Inspection
05/02/16PRICE SENSITIVE
MMJ Quarterly Update Report
01/02/16
MMJ Appendix 4C - quarterly
01/02/16PRICE SENSITIVE
MMJ MMJ Receives Notice of Pre-Licence Inspection at Duncan
14/01/16PRICE SENSITIVE
MMJ Trading Halt
13/01/16PRICE SENSITIVE
MMJ Appendix 3B
10/12/15
MMJ Results of Meeting
24/11/15
MMJ Investor Presentation
23/11/15
MMJ Satipharm Completes Wholesale Transaction
19/11/15PRICE SENSITIVE
MMJ Duncan Facility Ready for Immediate Pre-License Inspection
04/11/15
MMJ Quarterly Update Report
02/11/15
MMJ Appendix 4C - quarterly
02/11/15PRICE SENSITIVE
MMJ Phase 1 Clinical Trial Commences
27/10/15
MMJ Broker Research Report
26/10/15
MMJ Notice of Annual General Meeting/Proxy Form
23/10/15
MMJ Capital Raising & MMJ to Enter Australian MC Market
23/10/15PRICE SENSITIVE
MMJ Trading Halt
21/10/15PRICE SENSITIVE
MMJ Market Update
13/10/15PRICE SENSITIVE
MMJ Innovations TV Series to Showcase MMJ on Discovery Channel
09/10/15
MMJ Broker Research Report
08/10/15
MMJ Annual Report to shareholders
07/10/15
MMJ Appendix 3B - Quotation of Restricted Securities
17/09/15
MMJ Appendix 3B
08/09/15
MMJ Release of Shares from Mandatory Escrow
03/09/15
MMJ Results of Meeting
03/09/15
MMJ Appendix 4G
01/09/15
MMJ Appendix 4E and Full Year Statutory Accounts
01/09/15PRICE SENSITIVE
MMJ First Revenues Generated Upon Launch of Satipharm.com
31/08/15PRICE SENSITIVE
MMJ Trading Halt
27/08/15PRICE SENSITIVE
MMJ Appendix 3B
26/08/15
MMJ MMJ to Commence Phase 1 Clinical Study Late 2015
24/08/15PRICE SENSITIVE
MMJ Becoming a substantial holder
21/08/15
MMJ Final Director's Interest Notice x 2
21/08/15
MMJ Board and Leadership Changes
20/08/15
MMJ APP Securities Research Report
18/08/15
MMJ Managing Director's Letter to Shareholders
10/08/15
MMJ Completion of Capital Raising
05/08/15
MMJ Notice of General Meeting/Proxy Form
04/08/15
MMJ Initial Director's Interest Notice (Replacement)
03/08/15
MMJ MD Remuneration & Directors' Interests Notices
03/08/15
MMJ Quarterly Activities Report
31/07/15
MMJ Appendix 4C - quarterly
31/07/15PRICE SENSITIVE
MMJ PhytoTech MMJ Merger and Capital Raising Completed
28/07/15PRICE SENSITIVE
MMJ Appendix 3B
28/07/15
MMJ Trading Halt
23/07/15PRICE SENSITIVE
MMJ Investor Presentation - Replacement
14/07/15
MMJ Investor Presentation
14/07/15
MMJ PYL Significantly Expands Medical Cannabis Product Portfolio
13/07/15PRICE SENSITIVE
MMJ ASX Waiver of Listing Rule 14.7
10/07/15
MMJ Oral Formulations Advance Towards Phase 1 Clinical Trials
06/07/15PRICE SENSITIVE
MMJ MMJ Merger Unconditional
02/07/15
MMJ Results of Meeting
29/06/15
MMJ PhytoTech Launches New Website
23/06/15
MMJ PYL and MMJ on Track for Revenues in July
28/05/15PRICE SENSITIVE
MMJ Notice of General Meeting/Proxy Form
25/05/15
MMJ PYL-MMJ Merger Update
25/05/15PRICE SENSITIVE
MMJ Appendix 3B
08/05/15
MMJ Yissum Licensing Agreement Amendment
07/05/15PRICE SENSITIVE
MMJ Appendix 4C - quarterly
28/04/15PRICE SENSITIVE
MMJ Presentation
21/04/15
MMJ PYL-MMJ Investor Presentation
20/04/15
refresh Created with Sketch. REFRESH
 

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
ASX Market Close: ASX closes above 8,400pts on green Wednesday | Nov 27, 2024 The ASX finished up around 8,400 points after flirting with the 8,410 level throughout the day, clearly, in a good mood.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.